Studying a New Investigational Drug in the Fight Against Low-Grade Glioma

The INDIGO Study is a Phase 3 clinical trial evaluating the safety and effectiveness of vorasidenib in people with Grade 2 low-grade gliomas with an IDH mutation. If you are interested in participating, this site can provide information and guidance to help you discuss next steps with your doctor.

The INDIGO Study and low-grade glioma

If your doctor has spoken with you about low-grade glioma, you probably know the available options for treatment are limited. Your doctor may have talked about a “watch and wait” period, during which your medical team will monitor your disease on a regular basis and determine when a treatment such as chemotherapy and radiation might be needed.1

The INDIGO study is testing a new investigational drug called vorasidenib that targets IDH mutations present in the tumor.  These mutations occur in about 70-80% of Grade 2 and Grade 3 gliomas, as well as secondary glioblastomas.2  This study will investigate vorasidenib in people with Grade 2 glioma with an IDH mutation who are currently being managed in a watch and wait period.

Eligibility for the Study

There are a number of requirements and tests involved to ensure you are eligible for the study, such as determining whether you have a Grade 2 glioma with an IDH1 or IDH2 mutation.3

Explore the requirements

What to Expect

Find out what to expect during the study, and download a discussion guide to help inform your conversation with your doctor.

See an overview of the study schedule

Burst design
Icon of a stethoscope

Detailed Information for HCPs

See the INDIGO Study overview, study design, and how to enroll patients, along with information about IDH mutations.
Digital globe background design
Pharmacy location icon

Find an INDIGO Study site location near you


The effectiveness and safety of vorasidenib have not been established. There is no guarantee that vorasidenib will receive health authority approval or become commercially available in any country for the use being investigated.


  1. Weller M, van den Bent M, Tonn JC, et al. European Association for NeuroOncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18(6):e315-e329.
  2. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med. 2009; 360(8):765-773.
  3. Study of AG-881 in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) –